Addressing barriers to insulin therapy: The role of insulin pens

American Journal of Therapeutics

Volumn 18, Issue 5, 2011, Pages 392-402

  Magwire, Melissa L ^a  

^a Shawnee Mission Medical Center   (United States)

Author keywords

diabetes; injections; insulin; pen devices

Indexed keywords

INSULIN;

ARTICLE; CLINICAL PRACTICE; DRUG DELIVERY SYSTEM; HEALTH CARE COST; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN PEN; INSULIN TREATMENT; MEDICAL INSTRUMENTATION; MEDICAL TECHNOLOGY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT REFERRAL; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; TREATMENT INDICATION;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG COSTS; DRUG DELIVERY SYSTEMS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MEDICATION ADHERENCE; PATIENT PREFERENCE; QUALITY OF LIFE; UNITED STATES;

EID: 80052744912     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181ef4dde     Document Type: Article

References (66)

1. Brunton S. Insulin delivery systems: reducing barriers to insulin therapy and advancing diabetes mellitus treatment. Am J Med. 2008;121:S35-S41. (Pubitemid 351726337)
2. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diab Care. 2005;28:2673-2679. (Pubitemid 43951158)
3. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord. 2002; 26(Suppl 3):S18-S24. (Pubitemid 35034478)
4. Molife C, Lee LJ, Shi L, et al. Assessment of patientreported outcomes of insulin pen devices versus conventional vial and syringe. Diab Technol Ther. 2009;11:529-538.
5. Newman KD, Weaver MT. Insulin measurement and preparation among diabetic patients at a county hospital. Nurse Pract. 1994;19:44-45, 48.
6. Coscelli C, Calabrese G, Fedele D, et al. Use of premixed insulin among the elderly. Reduction of errors in patient preparation of mixtures. Diab Care. 1992;15:1628-1630.
7. Centers for Disease Control and Prevention. National diabetes fact sheet, 2007. General information and national estimates on diabetes in the United States. Atlanta, GA: US Department of Health and Human Services; 2007.
8. Pfutzner A. FlexPen for the delivery of insulin: accuracy, injection force and patient preference. Expert Rev Med Dev. 2009;6:115-123.
9. Reimer T, Hohberg C, Pfutzner AH, et al. Intuitiveness, instruction time, and patient acceptance of a prefilled insulin delivery device and a reusable insulin delivery device in a randomized, open-label, crossover handling study in patients with type 2 diabetes. Clin Ther. 2008;30:2252-2262.
10. Goldstein HH. Pen devices to improve patient adherence with insulin therapy in type 2 diabetes. Postgrad Med. 2008;120:172-179.
11. Marcus A. Diabetes care-insulin delivery in a changing world. Medscape J Med. 2008;10:120.
12. Graff MR, McClanahan MA. Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. Clin Ther. 1998;20:486-496. (Pubitemid 28343501)
13. Korytkowski M, Niskanen L, Asakura T. FlexPen-: addressing issues of confidence and convenience in insulin delivery. Clin Ther. 2005;27(Suppl B):S89-S100. (Pubitemid 43866930)
14. Korytkowski M, Bell D, Jacobsen C, et al. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003;25:2836-2848. (Pubitemid 37510593)
15. Egekvist H, Bjerring P, Arendt-Nielsen L. Pain and mechanical injury of human skin following needle insertions. Eur J Pain. 1999;3:41-49. (Pubitemid 29166621)
16. Product Brochure-BD Needles.Available at: http://www. bd.com/resource.aspx?IDX=6142. Accessed June 7, 2010.
17. Instructions for Use-BDNano. Available at: http://www. bd.com/resource.aspx?IDX=16984. Accessed June 7, 2010.
18. BD AutoShield-Safety Pen Needle. Available at: http://www.bd.com/us/ diabetes/page.aspx?cat=7002&id=14166. Accessed June 7, 2010.
19. NovoFine-Autocover. Available at: http://www.novonordisk. com/images/diabetes/pdf/novofine-autocover-detail-A4.pdf. Accessed June 7, 2010.
20. NovoFine-Product Brochure. Available at: http://www. novonordisk.com/ images/diabetes/pdf/NF-Detail-aid-A4-LOW.pdf. Accessed June 8, 2010.
21. Unifine®Pentips®-How to use-choosing a pen needle. Available at: http://www.owenmumford.com/us/download.asp?id=50. Accessed June 7, 2010.
22. Arendt-Nielsen L, Egekvist H, Bjerring P. Pain following controlled cutaneous insertion of needles with different diameters. Somatosens Mot Res. 2006;23:37-43. (Pubitemid 44114991)
23. McKay M, Compion G, Lytzen L. A comparison of insulin injection needles on patients' perceptions of pain, handling, and acceptability: a randomized, open-label, crossover study in subjects with diabetes. Diab Technol Ther. 2009;11:195-201.
24. Iwanaga M, Kamoi K. Patient perceptions of injection pain and anxiety: a comparison of NovoFine 32-gauge tip 6mm and Micro Fine Plus 31-gauge 5 mm needles. Diab Technol Ther. 2009;11:81-86.
25. Sommavilla B, Jorgensen C, Jensen K. Safety, simplicity and convenience of a modified prefilled insulin pen. Expert Opin Pharmacother. 2008;9:2223-2232.
26. Pfutzner A, Reimer T, Hohberg C, et al. Prefilled insulin device with reduced injection force: patient perception and accuracy. Curr Med Res Opin. 2008;24:2545-2549.
27. Rissler J, Jorgensen C, Rye HM, et al. Evaluation of the injection force dynamics of a modified prefilled insulin pen. Expert Opin Pharmacother. 2008;9:2217-2222.
28. Asakura T, Seino H, Kageyama M, et al. Evaluation of injection force of three insulin delivery pens. Expert Opin Pharmacother. 2009;10:1389-1393.
29. Ignaut DA, Opincar MR, Clark PE, et al. Engineering study comparing injection force and dose accuracy between two prefilled insulin injection pens. Curr Med Res Opin. 2009;25:2829-2833.
30. Savas S, Koroglu BK, Koyuncuoglu HR, et al. The effects of the diabetes related soft tissue hand lesions and the reduced hand strength on functional disability of hand in type 2 diabetic patients. Diab Res Clin Pract. 2007;77: 77-83. (Pubitemid 46590476)
31. Ziegler D, Gries FA, Spuler M, et al. The epidemiology of diabetic neuropathy. DiaCAN Multicenter Study Group. Diabet Med. 1993;10(Suppl 2):S82-S86.
32. Rubin RR, Peyrot M. Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies. Diab Care. 2004;27: 2495-2497. (Pubitemid 39281409)
33. Sucic M, Galic E, Cabrijan T, et al. Patient acceptance and reliability of new Humulin-/Humalog-3.0 ml prefilled insulin pen in ten Croatian diabetes centres. Med Sci Monitor. 2002;8:PI21-PI26. (Pubitemid 34263058)
34. Martin JM, Llewelyn JA, Ristic S, et al. Acceptability and safety of a new 3.0 ml re-usable insulin pen (HumaPen) in clinical use. Diab Nutr Metab. 1999;12:306-309. (Pubitemid 30009009)
35. Bohannon NJV, Ohannesian JP, Burdan AL, et al. Patient and physician satisfaction with the Humulin/Humalog®pen, a new 3.0-mL prefilled pen device for insulin delivery. Clin Ther. 2000;22:1049-1067.
36. Roberts A, Thornley S. Health-care professional-reported usability of SoloStar®in a 3-month observational survey in everyday clinical practice. J Diab Sci Technol. 2007; 1(Suppl 1):A151.
37. Shelmet J, Schwartz S, Cappleman J, et al. Preference and resource utilization in elderly patients: InnoLet®versus vial/syringe. Diab Res Clin Pract. 2004;63:27-35. (Pubitemid 38018954)
38. Haak T, Edelman S, Walter C, et al. Comparison of usability and patient preference for the new disposable insulin device SoloStar versus FlexPen, Lilly disposable pen, and a prototype pen: an open-label study. Clin Ther. 2007;29:650-660. (Pubitemid 47016637)
39. Fischer JS, Edelman SV, Schwartz SL. United States patient preference and usability for the new disposable insulin device SoloStar versus other disposable pens. J Diab Sci Technol. 2008;2:1157-1160.
40. Asakura T, Seino H. Assessment of dose selection attributes with audible notification in insulin pen devices. Diab Technol Ther. 2005;7:620-626. (Pubitemid 41208625)
41. Hofman PL, Lawton SA, Peart JM, et al. An angled insertion technique using 6-mm needles markedly reduces the risk of intramuscular injections in children and adolescents. Diab Med. 2007;24:1400-1405. (Pubitemid 350179428)
42. Peragallo-Dittko V. Aspiration of the subcutaneous insulin injection: clinical evaluation of needle size and amount of subcutaneous fat. Diab Educ. 1995;21: 291-296.
43. Lteif AN, Schwenk WF. Accuracy of pen injectors versus insulin syringes in children with type 1 diabetes. Diab Care. 1999;22:137-140. (Pubitemid 29028310)
44. Gnanalingham MG, Newland P, Smith CP. Accuracy and reproducibility of low dose insulin administration using pen-injectors and syringes. Arch Dis Child. 1998;79:59-62. (Pubitemid 28331256)
45. Keith K, Nicholson D, Rogers D. Accuracy and precision of low-dose insulin administration using syringes, pen injectors, and a pump. Clin Pediatr. 2004;43:69-74. (Pubitemid 38112268)
46. International Organization for Standardization. ISO/CD 11608-1. Pen-injectors for medical use-Part 1: Peninjectors-requirements and test methods. Available at: http://www.iso.org/iso/catalogue-detail.htm?csnumber= 52525. Accessed April 21, 2010.
47. Asakura T, Seino H, Kageyama M, et al. Dosing accuracy of two insulin pre-filled pens. Curr Med Res Opin. 2008;24: 1429-1434. (Pubitemid 351741576)
48. Hanel H, Weise A, Sun W, et al. Differences in the dose accuracy of insulin pens. J Diab Sci Technol. 2008;2: 478-481.
49. Cramer JA, Pugh MJ. The influence of insulin use on glycemic control: how well do adults follow prescriptions for insulin? Diab Care. 2005;28:78-83. (Pubitemid 40095786)
50. Morris AD, Boyle DI, McMahon AD, et al. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. Lancet. 1997;350: 1505-1510. (Pubitemid 28036554)
51. Donnelly LA, Morris AD, Evans JM. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. QJM. 2007;100:345-350. (Pubitemid 47073810)
52. Pladevall M, Williams LK, Potts LA, et al. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diab Care. 2004;27: 2800-2805. (Pubitemid 39565040)
53. Hepke KL, Martus MT, Share DA. Costs and utilization associated with pharmaceutical adherence in a diabetic population. Am J Manag Care. 2004;10:144-151. (Pubitemid 38332389)
54. Vijan S, Hayward RA, Ronis DL, et al. Brief report: the burden of diabetes therapy: implications for the design of effective patient-centered treatment regimens. J Gen Intern Med. 2005;20:479-482. (Pubitemid 40980453)
55. Meece J. Effect of insulin pen devices on the management of diabetes mellitus. Am J Health Sys Pharm. 2008;65: 1076-1082. (Pubitemid 351768744)
56. Lee WC, Balu S, Cobden D, et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther. 2006;28:1712-1725. (Pubitemid 44841979)
57. Cobden D, Lee WC, Balu S, et al. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy. 2007;27: 948-962. (Pubitemid 46986681)
58. De Luis DA, Aller R, Cuellar L, et al. Effect on quality of life with a new insulin injection device in elderly patients with diabetes mellitus type 2. J Diab Compl. 2004;18: 216-219. (Pubitemid 38781136)
59. Lee IT, Liu HC, Liau YJ, et al. Improvement in healthrelated quality of life, independent of fasting glucose concentration, via insulin pen device in diabetic patients. J Eval Clin Pract. 2009;15:699-703.
60. Albano S. Assessment of quality of treatment in insulintreated patients with diabetes using a pre-filled insulin pen. The ORBITER Study Group. Acta Biomedica Ateneo Parmense. 2004;75:34-39.
61. Pawaskar MD, Camacho FT, Anderson RT, et al. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther. 2007;29:1294-1305. (Pubitemid 351172225)
62. Edwards C, Metcalfe L, Allan J, et al. Reducing the risk of injuries to staff from insulin pens. Nurs Times. 2005;101: 34-36.
63. Davis EM, Bebee A, Crawford L, et al. Nurse satisfaction using insulin pens in hospitalized patients. Diab Educ. 2009;35:799-809.
64. Da Costa S, Brackenridge B, Hicks D. A comparison of insulin pen use in the United States and the United Kingdom. Diab Educ. 2002;28:52-60.
65. Peyrot M, Rubin RR. Physician perception and recommendation of insulin pens for patients with type 2 diabetes mellitus. Curr Med Res Opin. 2008;24:2413-2422.
66. Rubin RR, Peyrot M. Factors affecting use of insulin pens by patients with type 2 diabetes. Diab Care. 2008;31: 430-432.